Safety, tolerability, and feasibility of high-dose naltrexone in alcohol dependence: An open-label study

Human Psychopharmacology

Volumn 26, Issue 2, 2011, Pages 125-132

  Yoon, Gihyun ^a,b   Kim, Suck Won ^b   Thuras, Paul ^a,b   Westermeyer, Joseph ^a,b  

^a VA MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

alcoholism; clinical trial; craving; high dose; naltrexone; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; NALTREXONE; PROCHLORPERAZINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ALCOHOLISM; AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRINKING BEHAVIOR; DROWSINESS; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHORIA; FEASIBILITY STUDY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; LIBIDO; LIVER FUNCTION TEST; MALE; MORNING DOSAGE; NAUSEA; OUTCOME ASSESSMENT; OUTPATIENT CARE; PILOT STUDY; PRIORITY JOURNAL; SIDE EFFECT; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; ALCOHOLISM; DIZZINESS; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NAUSEA; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 79956262885     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1183     Document Type: Article

References (48)

1. Anton RF, Moak DH, Latham PK., 1996. The obsessive compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry 53: 225-231. (Pubitemid 26085204)
2. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK., 1999. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156: 1758-1764. (Pubitemid 29517569)
3. Anton RF, O'Malley SS, Ciraulo DA, et al. 2006. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003-2017. (Pubitemid 44794003)
4. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Press: Washington, DC.
5. Bouza C, Angeles M, Munoz A, Amate JM., 2004. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99: 811-828. (Pubitemid 38869838)
6. Brewer C, Wong VS., 2004. Naltrexone: report of lack of hepatotoxicity in acute viral hepatitis, with a review of the literature. Addict Biol 9: 81-87. (Pubitemid 38608490)
7. First MB, Spitzer RL, Gibbon M, Williams JB., 1995. Structured Clinical Interview for DSM-IV Axis I and Axis II disorders-Patient Edition (SCID-IP, Version 2.0). New York State Psychiatric Institute: New York.
8. Garbutt JC, Kranzler HR, O'Malley SS, et al. 2005. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 293: 1617-1625. (Pubitemid 40471792)
9. Guy W., 1976. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare: Washington, DC.
10. Hamilton M., 1959. The assessment of anxiety states by rating. Br J Med Psychol 32: 50-55.
11. Hamilton M., 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
12. Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD., 2001. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychopharmacol 21: 287-292. (Pubitemid 32452933)
13. Kim SW., 1998. Opioid antagonists in the treatment of impulse-control disorders. J Clin Psychiatry 59: 159-164. (Pubitemid 28208329)
14. Kim SW, Grant JE., 2001. An open naltrexone treatment study in pathological gambling disorder. Int Clin Psychopharmacol 16: 285-289. (Pubitemid 32822448)
15. Kim SW, Grant JE, Adson DE, Remmel RP., 2001a. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol 21: 632-634. (Pubitemid 33116674)
16. Kim SW, Grant JE, Adson DE, Shin YC., 2001b. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry 49: 914-921. (Pubitemid 32493813)
17. Kim SW, Grant JE, Yoon G, Williams KA, Remmel RP., 2006. Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients. Clin Neuropharmacol 29: 77-79. (Pubitemid 44357156)
18. Knopman DS, Hartman M., 1986. Cognitive effects of high-dose naltrexone in patients with probable Alzheimer's disease. J Neurol Neurosurg Psychiatry 49: 1321-1322.
19. Kranzler HR, Van Kirk J., 2001. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335-1341. (Pubitemid 32868343)
20. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA., 2001. Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734-1739.
21. Mark TL, Kranzler HR, Song X., 2003. Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend 71: 219-228. (Pubitemid 38368573)
22. Marrazzi MA, Wroblewski JM, Kinzie J, Luby ED., 1997. High-dose naltrexone and liver function safety. Am J Addict 6: 21-29. (Pubitemid 27089039)
23. McCaul ME, Wand GS, Rohde C, Lee SM., 2000. Serum 6-beta-naltrexol levels are related to alcohol responses in heavy drinkers. Alcohol Clin Exp Res 24: 1385-1391.
24. McLellan AT, Luborsky L, Woody GE, O'Brien CP., 1980. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis 168: 26-33. (Pubitemid 10187569)
25. Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, Pfohl D., 1987. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry 22: 35-42. (Pubitemid 17229950)
26. Monterosso JR, Flannery BA, Pettinati HM, et al. 2001. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10: 258-268. (Pubitemid 32879092)
27. Monti PM, Rohsenow DJ, Hutchison KE, et al. 1999. Naltrexone's effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23: 1386-1394. (Pubitemid 29409353)
28. O'Brien CP., 2001. Naltrexone for alcohol dependence: compliance is a key issue. Addiction 96: 1857. (Pubitemid 34014265)
29. O'Brien CP., 2005. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 162: 1423-1431. (Pubitemid 41105556)
30. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B., 1992. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49: 881-887.
31. Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP., 1999. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. J Subst Abuse Treat 16: 163-167. (Pubitemid 29066428)
32. Oslin DW, Berrettini W, Kranzler HR, et al. 2003. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546-1552. (Pubitemid 41070891)
33. Petrakis IL, Leslie D, Rosenheck R., 2003. Use of naltrexone in the treatment of alcoholism nationally in the Department of Veterans Affairs. Alcohol Clin Exp Res 27: 1780-1784. (Pubitemid 37444365)
34. Pettinati HM, Weiss RD, Dundon W, et al. 2005. A structured approach to medical management: a psychosocial intervention to support pharmacotherapy in the treatment of alcohol dependence. J Stud Alcohol 66 (Suppl 15): 170-178. (Pubitemid 41193192)
35. Pettinati HM, Kampman KM, Lynch KG, et al. 2008. Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence. J Subst Abuse Treat 34: 378-390. (Pubitemid 351609292)
36. Pfohl DN, Allen JI, Atkinson RL, et al. 1986. Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr 67: 66-72. (Pubitemid 17193505)
37. Sax DS, Kornetsky C, Kim A., 1994. Lack of hepatotoxicity with naltrexone treatment. J Clin Pharmacol 34: 898-901. (Pubitemid 24321074)
38. Sheehan DV., 1983. The Anxiety Disease. Charles Scribner & Sons: New York.
39. Sinclair JD., 2001. Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism. Alcohol Alcohol 36: 2-10. (Pubitemid 32099659)
40. Sobell LC, Sobell MB., 1992. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In Measuring Alcohol Consumption, Litten R, Allen J, (eds). Humana Press: Totowa, NJ; 41-72.
41. Sofuoglu M, Kosten TR., 2004. Pharmacologic management of relapse prevention in addictive disorders. Psychiatr Clin North Am 27: 627-648. (Pubitemid 39535120)
42. Srisurapanont M, Jarusuraisin N., 2005. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 8: 267-280. (Pubitemid 40769268)
43. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM., 1989. Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment For Alcohol Scale (CIWA-Ar). Br J Addict 84: 1353-1357. (Pubitemid 19281139)
44. Swift RM., 2003. Topiramate for the treatment of alcohol dependence: initiating abstinence. Lancet 361: 1666-1667. (Pubitemid 36577434)
45. Verebey KG, Mule SJ., 1986. Naltrexone (Trexan): a review of hepatotoxicity issues. NIDA Res Monogr 67: 73-81. (Pubitemid 17193506)
46. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP., 1992. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876-880.
47. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP., 1997. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54: 737-742. (Pubitemid 27344101)
48. Yoon G, Kim SW, Thuras P, Grant JE, Westermeyer J., 2006. Alcohol craving in outpatients with alcohol dependence: rate and clinical correlates. J Stud Alcohol 67: 770-777. (Pubitemid 44162737)